semaglutide sglt2 inhibitor Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application SGLT2 Inhibitors vs. GLP-1 Agonists – SGLT2 Inhibitors: A New Class

[6] Regulatory bodies including the MHRA and EMA have included pancreatitis as a potential adverse effect in the prescribing information for GLP-1 agonists

They slow down the digestion and absorption of carbohydrates, preventing spikes in blood sugar levels

Semaglutide GLP-1 is typically prescribed for approximately a year of usage, which patients can expect to lose approximately 15% of their overall weight

Currently approved peptide treatments such as semaglutide 2.4 mg (Wegovy) are available under NICE TA875 for adults with BMI 35 kg/m and a weight-related comorbidity, delivered within a specialist weight management service